Mix-and-Match COVID boosters tested in african teens and adults

NCT ID NCT07408297

Completed ⭐️ VACCINE ⭐️ Sponsor: Victoria Biomedical Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested different COVID-19 booster vaccines (Janssen, Moderna, Pfizer, Novavax) in about 1,900 adolescents and adults aged 12 to 64 in Kenya, Democratic Republic of Congo, and Rwanda. Some participants had HIV, and others did not. The goal was to see if mixing vaccine types for a booster shot is safe and boosts immunity. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COVID-19 vaccines (Janssen Ad26COVS1, Moderna mRNA-1273, Pfizer-BioNTech, Novavax NVX-CoV2373)
What this could lead to: If successful, this could show that mixing different COVID-19 booster vaccines is safe and effective, especially for people with HIV, helping improve vaccine access in Africa.
What could go wrong: This is a phase 2 trial, so results are still early. The study focuses on immune response and safety, not direct prevention of COVID-19 illness. Different vaccine combinations may not all work equally well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 SARS-COV-2 INFECTION

Contacts and locations

Locations

Victoria Biomedical Research Institute

Kisumu, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.